Sulfinpyrazone
From Wikipedia, the free encyclopedia
(Redirected from Anturane)
 |
|
| Systematic (IUPAC) name | |
|---|---|
| 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione | |
| Identifiers | |
| CAS number | 57-96-5 |
| ATC code | M04AB02 |
| PubChem | 5342 |
| DrugBank | APRD00620 |
| Chemical data | |
| Formula | C23H20N2O3S |
| Mol. mass | 404.48 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98–99% |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | oral intravenous |
 (what is this?) (verify) |
|
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
[edit] Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]
[edit] References
- ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ 332 (7553): 1315–9. doi:. PMID 16740561.
|
|||||||||||||||||||||||
|
|||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
